Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Toppari, Jorma

IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

See all formats and pricing
More options …
Volume 29, Issue 7


17-Hydroxyprogesterone responses to human chorionic gonadotropin are not associated with serum anti-Mullerian hormone levels among adolescent girls with polycystic ovary syndrome

Jingwen Hou / Heidi Cook-Andersen / H. Irene Su / Rana Shayya / Kevin H. Maas / Christine M. Burt-Solorzano
  • Department of Pediatrics, Center for Research in Reproduction, University of Virginia Charlottesville, VA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ajay Kumar / R. Jeffrey Chang
Published Online: 2016-05-11 | DOI: https://doi.org/10.1515/jpem-2015-0461


Background: In adult women with polycystic ovary syndrome (PCOS) 17-OHP responses to human chorionic gonadotropin (hCG) stimulation are highly variable and inversely correlated with serum anti-Mullerian hormone (AMH) levels. The objective of this study was to determine whether adolescents with PCOS exhibit similar variable 17-OHP responsiveness to hCG and whether these responses are correlated to AMH levels.

Methods: In a prospective study, adolescent PCOS (n=14) and normal controls (n=10) received 25 μg of hCG, intravenously. Blood samples were obtained before and 24 h afterwards for measurement of 17-OHP and basal AMH.

Results: Variable 17-OHP responses to hCG were observed among PCOS girls similar to that observed in adults. There was no correlation between AMH and 17-OHP responses to hCG.

Conclusions: Among adult and adolescent individuals with PCOS variable 17-OHP production appears to be characteristic of the disorder. In adolescent PCOS, 17-OHP responsiveness to hCG is not correlated to AMH.

Keywords: adolescent; anti-Mullerian hormone; 17-hydroxyprogesterone; polycystic ovary syndrome


  • 1.

    Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Boston, MA: Blackwell Scientific, 1992:377–84.Google Scholar

  • 2.

    Rotterdam. ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.Google Scholar

  • 3.

    Rosenfield RL, Barnes RB, Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994;79:1686–92.Google Scholar

  • 4.

    Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 1997;47:93–9.Google Scholar

  • 5.

    Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, et al. Antimullerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012;98:242–9.Web of ScienceGoogle Scholar

  • 6.

    Ibanez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab 1999;84:2691–5.Google Scholar

  • 7.

    Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992;327: 157–62.Google Scholar

  • 8.

    Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A. 17-Hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:4208–17.Web of ScienceGoogle Scholar

  • 9.

    Maas KH, Chuan SS, Cook-Andersen H, Su HI, Duleba AJ, et al. Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015;100:293–300.Google Scholar

  • 10.

    Campbell BK, Clinton M, Webb R. The role of anti-Mullerian hormone (AMH) during follicle development in a monovulatory species (sheep). Endocrinology 2012;153:4533–43.Web of ScienceGoogle Scholar

  • 11.

    Crisosto N, Sir-Petermann T, Greiner M, Maliqueo M, Moreno M, et al. Testosterone-induced downregulation of anti-Mullerian hormone expression in granulosa cells from small bovine follicles. Endocrine 2009;36:339–45.Web of ScienceGoogle Scholar

  • 12.

    Rodrigues JK, Navarro PA, Zelinski MB, Stouffer RL, Xu J. Direct actions of androgens on the survival, growth and secretion of steroids and anti-Mullerian hormone by individual macaque follicles during three-dimensional culture. Hum Reprod 2015;30:664–74.Web of ScienceGoogle Scholar

  • 13.

    Ibanez L, Potau N, Zampolli M, Prat N, Gussinye M, et al. Source localization of androgen excess in adolescent girls. J Clin Endocrinol Metab 1994;79:1778–84.Google Scholar

  • 14.

    Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr 2015;83:376–89.Google Scholar

  • 15.

    Opinion AC. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Obstet Gynecol 2006;108:1323–81.Google Scholar

  • 16.

    Ibanez L, Potau N, Virdis R, Zampolli M, Terzi C, et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1599–603.Google Scholar

  • 17.

    Pellatt L, Hanna L, Brincat M, Galea R, Brain H, et al. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92:240–5.Web of ScienceGoogle Scholar

  • 18.

    Pierre A, Peigne M, Grynberg M, Arouche N, Taieb J, et al. Loss of LH-induced down-regulation of anti-Mullerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum Reprod 2013;28:762–9.Google Scholar

  • 19.

    Cook-Andersen H, Chuan SS, Maas K, Rosencrantz MA, Su HI, et al. Lack of serum anti-mullerian hormone responses after recombinant human chorionic gonadotropin stimulation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015;100:251–7.Web of ScienceGoogle Scholar

  • 20.

    Grynberg M, Pierre A, Rey R, Leclerc A, Arouche N, et al. Differential regulation of ovarian anti-mullerian hormone (AMH) by estradiol through alpha- and beta-estrogen receptors. J Clin Endocr Metab 2012;97:E1649–57.Web of ScienceGoogle Scholar

  • 21.

    Ibanez L, Hall JE, Potau N, Carrascosa A, Prat N, et al. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 1996;81:4103–7.Google Scholar

About the article

Corresponding author: R. Jeffrey Chang, MD, Department of Reproductive Medicine, University of California, School of Medicine, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0633, USA, Phone: +(858) 534-8930, Fax: +(868) 534-8856

Received: 2015-11-30

Accepted: 2016-03-29

Published Online: 2016-05-11

Published in Print: 2016-07-01

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This research was supported by the Eunice Kennedy Shriver NICHD/NIH through cooperative agreements (U54 HD12303-28 and U54 HD028934) as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research, K23 HD070854, NIH T32 HD007203, and in part by NIH grant MO1 RR00827. Clinical Trial Registration Number: NCT01154192.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 29, Issue 7, Pages 835–840, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2015-0461.

Export Citation

©2016 by De Gruyter.Get Permission

Comments (0)

Please log in or register to comment.
Log in